Capital Advisory Group Advisory Services’s Takeda Pharmaceutical TAK Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-403	Closed	-$6K	–	453
2022 Q1	$6K	Buy	+403	New	+$5.92K	﹤0.01%	424
2021 Q4	–	Sell	-403	Closed	-$7K	–	459
2021 Q3	$7K	Hold	403	–	–	﹤0.01%	441
2021 Q2	$7K	Hold	403	–	–	﹤0.01%	437
2021 Q1	$7K	Hold	403	–	–	﹤0.01%	426
2020 Q4	$7K	Sell	403 -95	-19%	-$1.67K	﹤0.01%	409
2020 Q3	$9K	Buy	498 +95	+24%	+$1.73K	﹤0.01%	332
2020 Q2	$7K	Hold	403	–	–	﹤0.01%	344
2020 Q1	$6K	Buy	+403	New	+$7.3K	0.01%	293

Other funds holding TAK

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Advisory Group Advisory Services's TAK Position: Q2 2022 in Review

Capital Advisory Group Advisory Services sold out of Takeda Pharmaceutical (TAK) in Q2 2022, closing a stake of 403 shares — an estimated $6K sold.

Capital Advisory Group Advisory Services first reported a position in TAK in Q1 2020 and held it in 8 quarters. The position peaked at $9K in Q3 2020. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

Capital Advisory Group Advisory Services reported no remaining Takeda Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 403 Takeda Pharmaceutical shares in Q2 2022, an estimated $6K.
Capital Advisory Group Advisory Services first reported a position in Takeda Pharmaceutical in Q1 2020 and held it in 8 quarters.
Capital Advisory Group Advisory Services's Takeda Pharmaceutical position peaked at $9K in Q3 2020.
283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Capital Advisory Group Advisory Services's 13F filing for Q2 2022, filed 12 Aug 2022.